홍은진
홍은진 교수
전공임상약동학, 계량약리학, 임상약리학, 규제과학
연락처
031-881-7108
ejhong1@cha.ac.kr
학력
- 서울대학교 약학과 학사
- 서던캘리포니아대학교(University of Southern California) 약학대학 규제과학 석사
- 서던캘리포니아대학교(University of Southern California) 약학대학 임상약학 박사
경력
- 현)차의과학대학교 임상약학대학원 조교수
- 현)차의과학대학교 약학대학 조교수
- University of Southern California, School of Pharmacy, 연구원
- 삼성바이오에피스 연구원
- Best Poster Presentation Award, KFDC 규제과학회, 2024.06
- Best Presentation Award, 대한임상노인의학회, 2024.05
[수상내역]
논문
- Eunjin Hong, Marco Zampoli, Paul Beringer. (2024). “Pharmacokinetic Enhancement of Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis: A Cost Reduction Strategy to Address Global Disparities in Access.” Clinical Pharmacology & Therapeutics,115(6), 1204-1207.
- Eunjin Hong, Sarah Parsons, Laura Sass, Cynthia Epstein, Lynn Chan, Claire Brown, Patricia H. Eshaghian, Paul Beringer. (2024). “Preliminary evidence for sustained efficacy of CFTR modulator therapy with concomitant rifabutin administration.” Journal of Cystic Fibrosis, 23(3), 519-523.
- Eunjin Hong, Alan Shi, Paul Beringer. (2023). “CFTR modulator drug interactions: a review of the evidence and clinical implications.” Expert Opinion on Drug Metabolism & Toxicology, 19(4), 203-216.
- Eunjin Hong, Eugeniu Carmanov, Alan Shi, Peter S Chung, Adupa P Rao, Kevin Forrester, Paul M Beringer. (2023). “Application of physiologically-based pharmacokinetic modeling to predict drug-drug interactions between ivacaftor and tacrolimus in lung transplant patients.” Pharmaceutics, 15(5), 1438.
- Tian Xia, Xin Wu, Eunjin Hong, Kyle Jung, Chih-Jen Lai, Mi-Jeong Kwak, Hogyu Seo, Stephanie Kim, Zhongyi Jiang, Inho Cha, Jae U Jung. (2023). “Glucosylceramide is essential for Heartland and Dabie bandavirus glycoprotein-induced membrane fusion.” PLoS Pathogen, 19(3), e1011232.
- Eunjin Hong, Regina Li, Alan Shi, Lisa M Almond, Joshua Wang, Amin Z Khudari, Soumar Haddad, Sarkis Sislyan, Marissa Angelich, Peter S Chung, Adupa P Rao, Paul M Beringer. (2023). "Safety of elexacaftor/tezacaftor/ivacaftor dose reductions: mechanistic exploration through physiologically based pharmacokinetic modeling and a clinical case series." Pharmacotherapy, 43(4), 291-299.
- Eunjin Hong, Lisa Almond, Peter S Chung, Adupa P Rao, Paul M Beringer. (2022). "Physiologically-Based Pharmacokinetic (PBPK) modeling to guide management of drug interactions between elexacaftor-tezacaftor-ivacaftor and antibiotics for the treatment of non-tuberculosis mycobacteria (NTM)." Antimicrobial Agents and Chemotherapy, 66(11), e0110422.
- Eunjin Hong, Lisa Almond, Peter S Chung, Adupa P Rao, Paul M Beringer. (2022). "Physiologically‐Based Pharmacokinetic‐Led Guidance for Patients with Cystic Fibrosis Taking Elexacaftor‐Tezacaftor‐Ivacaftor With Nirmatrelvir‐Ritonavir for the Treatment of COVID‐19." Clinical Pharmacology & Therapeutics, 111(6), 1324-1333.
- Weiqiang Chen, Suan-Sin Foo, Eunjin Hong, Christine Wu, Wai-Suet Lee, Shin-Ae Lee, Denis Evseenko, Maria Elisabeth Lopes Moreira, Adolfo García-Sastre, Genhong Cheng, Karin Nielsen-Saines, Patrícia Brasil, Elyzabeth Avvad-Portari, Jae U Jung. (2021). "Zika virus NS3 protease induces bone morphogenetic protein-dependent brain calcification in human fetuses." Nature Microbiology, 6(4), 455-466.